Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02338986 · ClinicalTrials.gov registry record
Collection of Plasma From People Who Recovered From or Were Vaccinated to Emerging Infectious Diseases
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 10
- Enrollment target
NCT02338986 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 10 participants.
The verdict
NCT02338986 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
Background: \- There are more emerging infectious diseases recently. Some could affect many people. Some like Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS) are caused by new germs. Sometimes known germs suddenly infect new and large areas, like Ebola. Many of these diseases don t have good treatments available. Researchers may be able to develop a treatment by using antibodies against these infections. Objective: \- To collect antibodies from people with high levels of antibodies to the diseases being studied. Eligibility: \- Ages 18-70 years old who weigh at least 110 pounds. They may have been infected with or vaccinated for one of the new infections researchers are studying. Design: * Participants will be screened with medical history and blood tests. Researchers will determine if the participant can have apheresis. * Participants will have apheresis. First, they will be interviewed. Then, a needle will be placed in a vein. Blood will be drawn, and a machine will separate the blood cells from the antibodies and protein. The blood cells will then be returned to the participant through another vein. It takes about 60 minutes for the actual collection. * Participants will be asked to have the procedure at least 3 times. They can participate in up to 20 sessions total as part of this study. There must be at least 7 days between sessions.
Interventions
- DRUG Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-03-04 |
| Est. Completion | 2025-05-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02338986
The ClinicalTrials.gov registry entry for NCT02338986 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Plasma is the first listed.
NCT02338986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02338986 about?
NCT02338986 is a clinical study titled "Collection of Plasma From People Who Recovered From or Were Vaccinated to Emerging Infectious Diseases". Background: \- There are more emerging infectious diseases recently. Some could affect many people. Some like Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS) are caused by new germs. Sometimes known germs suddenly infect new and large areas, like Ebola. Many of t...
What is the current status of trial NCT02338986?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2015-03-04. Estimated completion is 2025-05-15.
What interventions are being tested in trial NCT02338986?
The interventions under investigation include: Plasma (DRUG).
Who is sponsoring clinical trial NCT02338986?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.